跳至主要内容
临床试验/EUCTR2005-004422-50-FI
EUCTR2005-004422-50-FI进行中(未招募)不适用

A placebo-controlled, double-blind, cross-over study with rupatadine 10 mg in 30 mosquito-bite allergic adult subjectsRupatadiini-antihistamiini hyttyspistoallergiassa - Rupatadiini-antihistamiini hyttyspistoallergiassa

J.Uriach y Compania S.A.,0 个研究点目标入组 30 人开始时间: 2005年12月7日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Mosquito-bite allergic subjects, mostly physicians, nurses and other health care personnel from the files of the investigators will be asked to participate in the study. Eligible subjects are defined by the following inclusion and exclusion criteria and a total of 30 subjects will included in the study.
  • Inclusion criteria
  • 1.Male or female, age 18 - 65 years.
  • 2.History of suffering from mosquito-bite reactions and showing at inclusion at least 5 mm diameter wheal from Aedes aegypti laboratory mosquito bite.
  • 3.Written informed consent to participate in the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Exclusion criteria
  • Assessed at screening, prior to randomization:
  • 1.Pregnancy or lactating females
  • 2.Oral antihistamines, corticosteroid or non-steroid anti-inflammatory drug (NSAID) use within two weeks before the study
  • 3.Severe or moderate systemic illness
  • 4.Anaphylaxis from mosquito bites
  • 5.Allergy to rupatadine or other antihistamines

研究者

发起方
J.Uriach y Compania S.A.,

相似试验